DEVRO LIMITED

Financial Health Score: B

Explanation: Devro Limited exhibits a strong and steady corporate "heartbeat" in terms of administrative compliance, but the lack of publicly visible financial "blood work" (detailed balance sheet metrics) prevents a higher score. The company recently underwent major structural "surgery" (transitioning from a PLC to a Private Limited Company), which is typically a symptom of an acquisition. While administrative health is excellent, the extremely low share capital (£17) and opaque financial metrics mean we must rely on secondary vital signs to assess the underlying tissue health of the business.

Key Vital Signs

• Compliance Pulse: Strong. The company’s filings are fully up to date, with accounts made up to December 2024 and confirmation statements current. There are no symptoms of administrative distress or regulatory fever.
• Corporate Lineage & Age: Mature. Incorporated in 1991, the business has over three decades of operational history, indicating a robust immune system capable of surviving economic cycles.
• Capital Blood Count: Abnormally Low. Share capital stands at a mere £17. While this looks like a symptom of severe anemia, it is actually a common blood type for a corporate holding entity or a company that has undergone a recent acquisition and capital restructuring.
• Organ Function (SIC Code): Central Nervous System. Classified under SIC 70100 (Activities of head offices), Devro Limited acts as the brain rather than the muscle. It manages strategic direction for its subsidiaries rather than engaging in direct manufacturing or retail, despite its website indicating a global sausage casing operation.
• PSC (Significant Control) Profile: Shielded. The PSC register contains only a statement, meaning the ultimate parent company is likely exercising control from above, a common structural symptom following an acquisition.

Diagnosis

The patient is structurally transformed but fundamentally stable. In April 2023, the company underwent significant corporate surgery, changing from "Devro PLC" to "Devro Limited." This transition, combined with an international board of directors and the opaque PSC register, strongly indicates that the company has been acquired (Devro PLC was acquired by Saria, a German group, in early 2023) and now operates as the UK holding/topco for the wider group's operations.

The £17 share capital is not a symptom of financial distress, but rather a classic presentation of a holding company that has restructured its equity, likely pushing operational capital and retained earnings down to subsidiary level or extracting it via inter-company dividends. Because the company files as a "Full" category but functions as a head office, the vital signs we can observe (compliance, corporate structure) are healthy. However, the true financial blood pressure (cash flow, operating margins) is hidden within the group's consolidated veins, making a precise operational diagnosis impossible from the exterior.

Recommendations

1. Monitor Inter-Company Arteries: As a head office entity, Devro Limited’s financial wellness depends on the health of its subsidiaries. Ensure regular "check-ups" on subsidiary performance, inter-company loan balances, and dividend flows to ensure the head office has adequate cash flow circulation.
2. Maintain Compliance Hygiene: The company has an excellent record of meeting its regulatory deadlines. Continue this preventive care to avoid unnecessary regulatory penalties or "infections" from Companies House.
3. Governance Check-Ups: With an international board of directors spanning Dutch, Australian, Danish, and New Zealand nationalities, it is vital to maintain rigorous corporate governance protocols. Ensure that board resolutions are properly documented and that the directors' fiduciary duties are clearly aligned across different jurisdictions.